FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

GHRP-6

Growth Hormone Releasing Peptide-6

Growth Hormone Secretagogues

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that potently stimulates growth hormone release by acting as a ghrelin mimetic at the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary gland. It was one of the first synthetic GH secretagogues developed and is notable for producing robust GH pulses along with significant appetite stimulation through ghrelin pathway activation. Research applications include GH deficiency assessment, muscle wasting conditions, and studies of appetite regulation and metabolic function.

Wirkmechanismus

First-generation synthetic hexapeptide GHSR agonist. Potent ghrelin mimetic that stimulates GH release and strongly increases appetite. Also activates the vagus nerve, promoting gastroprotective effects and gastric motility. Less selective than ipamorelin or GHRP-2.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research protocols use 100-300mcg 2-3 times daily via subcutaneous injection on an empty stomach. Expect significant hunger increase within 20 minutes of injection. Often combined with CJC-1295 no DAC.

Forschungsnotizen

Clinical Research Status

GHRP-6 has been extensively studied in clinical research settings since the early 1990s as both a diagnostic tool for GH deficiency and a potential therapeutic agent for catabolic conditions. It has been used in over 100 published clinical studies as a GH provocation test, often combined with GHRH for maximal diagnostic sensitivity. While widely available through compounding pharmacies and research suppliers, GHRP-6 has not received FDA approval for any therapeutic indication, though it remains an important research tool in endocrinology.

Key Published Findings

Clinical studies demonstrate that GHRP-6 produces dose-dependent GH release with peak plasma levels occurring 15-30 minutes after subcutaneous administration, with typical GH elevations of 5-15 fold above baseline. Research has confirmed that GHRP-6 stimulates GH release through a mechanism complementary and synergistic with GHRH, producing greater combined GH output than either peptide alone. Studies in elderly subjects show preserved GHRP-6 responsiveness compared to the age-related decline in GHRH efficacy, suggesting the ghrelin pathway remains functional in aging.

Safety Profile

GHRP-6 is well-tolerated in clinical studies with transient side effects including facial flushing, mild dizziness, and intense hunger occurring shortly after administration. Cortisol and prolactin elevations are modest and transient compared to the robust GH response. Chronic administration studies have not revealed significant safety concerns, though long-term data beyond 6-12 months of continuous use is limited in human subjects.

Drug Interactions & Contraindications

GHRP-6 may potentiate the effects of exogenous GH or GHRH when administered concurrently, requiring dose adjustments in individuals already on GH therapy. The significant appetite stimulation may counteract the effects of appetite suppressants or medications for weight management. Patients with diabetes should monitor blood glucose carefully, as acute GH release can transiently impair insulin sensitivity, and the appetite stimulation may affect glycemic control.

Comparison to Related Compounds

GHRP-6 produces notably stronger appetite stimulation than GHRP-2, Ipamorelin, or Hexarelin due to its high affinity for the ghrelin receptor and downstream activation of hunger signaling. Ipamorelin is often preferred for users who want GH release without appetite increase, as it is more selective for GH secretion with minimal effect on cortisol, prolactin, or appetite. Hexarelin produces the strongest absolute GH release of the GHRP family but undergoes rapid desensitization, while GHRP-6 maintains efficacy with repeated dosing.

Community Observations

Users consistently report intense hunger onset within 20-30 minutes of GHRP-6 injection, making it popular among those seeking to increase caloric intake for muscle gain but problematic for those pursuing fat loss. Typical dosing ranges from 100-300mcg subcutaneously 2-3 times daily, often administered 30 minutes before meals to capitalize on the appetite stimulation. The community frequently uses GHRP-6 in combination with Mod GRF 1-29 (CJC-1295 no DAC) to synergistically amplify GH output, with users reporting improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 months.

Halbwertszeit

~1-2 hours

Rekonstitution

Bacteriostatic water (BAC)

Lagerung

Lyophilisiert

Refrigerate 2-8C up to 18 months.

Rekonstituierter

Refrigerate 2-8C. Use within 14 days.

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

Growth Hormone Releasing Peptide-6

Häufig gestellte Fragen

Was ist GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that potently stimulates growth hormone release by acting as a ghrelin mimetic at the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary gland. It was one of the first synthetic GH secretagogues developed and is notable for producing robust GH pulses along with significant appetite stimulation through ghrelin pathway activation. Research applications include GH deficiency assessment, muscle wasting conditions, and studies of appetite regulation and metabolic function.

Wie wirkt GHRP-6?

First-generation synthetic hexapeptide GHSR agonist. Potent ghrelin mimetic that stimulates GH release and strongly increases appetite. Also activates the vagus nerve, promoting gastroprotective effects and gastric motility. Less selective than ipamorelin or GHRP-2.

Wie ist der regulatorische Status von GHRP-6 in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von GHRP-6?

~1-2 hours

Wie wird GHRP-6 noch genannt?

Growth Hormone Releasing Peptide-6

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen